Last reviewed · How we verify
LY2216684
LY2216684 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.
LY2216684 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders. Used for Major depressive disorder, Circadian rhythm sleep disorders.
At a glance
| Generic name | LY2216684 |
|---|---|
| Also known as | Edivoxetine |
| Sponsor | Eli Lilly and Company |
| Drug class | 5-HT7 receptor antagonist |
| Target | 5-HT7 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
The drug targets the 5-HT7 receptor, a G-protein coupled receptor involved in circadian rhythm regulation and mood control. By blocking this receptor, LY2216684 may help normalize sleep-wake cycles and improve mood symptoms. This mechanism is distinct from traditional SSRIs and may offer benefits in conditions where circadian dysregulation contributes to pathology.
Approved indications
- Major depressive disorder
- Circadian rhythm sleep disorders
Common side effects
- Headache
- Nausea
- Dizziness
- Insomnia
Key clinical trials
- A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder (PHASE2, PHASE3)
- A Study of LY2216684 and Theophylline in Healthy Subjects (PHASE1)
- A Study of LY2216684 in Healthy Participants (PHASE1)
- A Study of the Effect of LY2216684 on Lorazepam (PHASE1)
- A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together. (PHASE1)
- A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol (PHASE1)
- A Study of LY2216684 and Warfarin in Healthy Subjects (PHASE1)
- A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2216684 CI brief — competitive landscape report
- LY2216684 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI